


EPIFIX[®]

CARING FOR CHALLENGING CLOSURES WHEN PATIENTS NEED IT MOST



EPIFIX

Protective Barrier

- Supports the healing cascade
- Protects the wound bed to aid in the development of granulation tissue in acute and chronic wounds

Provides a Human Biocompatible Extracellular Matrix (ECM)

- **Structural components:**
Collagen I, III, IV; elastin
- **Cell-binding domains:**
Fibronectin, collagen V, VII
- **ECM-binding domains:**
Proteoglycans, laminin

Retains Regulatory Proteins

- 300+ Regulatory Proteins¹⁻³



- Dehydrated amnion/chorion membrane sheet allograft

- EPIFIX[®] is SMR²T[™] Technology

Selective Membrane of Reparative and Reconstructive Tissue



- Uses PURION[®] patented processing

EPIFIX®

Clinical Use Examples

- Comorbid patients with complex defects or delayed healing
- Diabetic foot ulcers (DFUs)
- Venous leg ulcers (VLUs)
- Debridements
- Decubitus ulcers

Product Advantages

- Most level I evidence in placental-based allografts: 6 EPIFIX RCTs
- SMR²T Technology and patented PURION processing
- Terminally sterilized for additional level of safety
- Easy to apply
- Room temperature storage
- 5-year shelf life
- Compatible with negative pressure wound therapy (NPWT) and hyperbaric oxygen therapy (HBO)

**Patient Insurance
Verification Team:
855.882.8480**



Patents and patents pending see: www.mimedx.com/patents. EPIFIX, PURION, SMR²T, and MIMEDX are trademarks of MIMEDX Group, Inc. ©2020 MIMEDX Group, Inc. All Rights Reserved. www.mimedx.com EP579.002

EPIFIX is a dehydrated human amnion/chorion membrane allograft. EPIFIX sheets provide a semi-permeable protective barrier that supports the healing cascade and protects the wound bed to aid in the development of granulation tissue in acute and chronic closures. EPIFIX provides a biocompatible human extracellular matrix and retains 300+ regulatory proteins.¹⁻³

Published Studies	N	Outcomes Observed in Studies
DFU RCT: ^{4,5} EPIFIX vs. Apligraf® vs. SOC	EPIFIX: 32 Apligraf: 33 SOC: 35	Complete wound closure: 85% at 4 weeks (EPIFIX vs. Apligraf $p=0.001$; EPIFIX vs. SOC $p=0.001$) 95% at 6 weeks (EPIFIX vs. Apligraf $p=0.0006$; EPIFIX vs. SOC $p=0.0001$) 97% at 12 weeks (EPIFIX vs. Apligraf $p=0.0001$; EPIFIX vs. SOC $p=0.0001$)
VLU Multicenter RCT: ^{6,7} EPIFIX vs. SOC	EPIFIX: 52 SOC: 57	Complete wound closure (Per Protocol): 60% at 12 weeks ($p=0.0128$) 71% at 16 weeks ($p=0.0065$)

Physician Office* Ordering Information

Item #	Size & Description
GS-5024	24 mm disk
GS-5330	3 cm x 3 cm sheet
GS-5350	3 cm x 5 cm sheet
GS-5460	4 cm x 6 cm sheet
GS-5560	5 cm x 6 cm sheet
GS-5770	7 cm x 7 cm sheet
Item #	Size & Description
ES-3500	3 cm x 5 cm mesh sheet
ES-4400	4 cm x 4.5 cm mesh sheet
ES-5500	5 cm x 5.5 cm mesh sheet



*Q Code: 4186

Apligraf is a registered trademark of Organogenesis.

SMR²T & Purion

REFERENCES: 1. Koob TJ, Lim JJ, Masee M, Zabeck N, Denozière G. Properties of dehydrated human amnion/chorion composite grafts: Implications for wound repair and soft tissue regeneration. *J Biomed Mater Res B Appl Biomater.* 2014;102(6):1353-1362. 2. Lei J, Priddy LB, Lim JJ, Masee M, Koob TJ. Identification of Extracellular Matrix Components and Biological Factors in Micronized Dehydrated Human Amnion/Chorion Membrane. *Adv Wound Care (New Rochelle).* 2017;6(2):43-53. 3. MM-RD-00086, Proteome Characterization of PURION Processed Dehydrated Human Amnion Chorion Membrane (dHACM) and PURION PLUS Processed Dehydrated Human Umbilical Cord (dHUC) Allografts. 4. Zelen CM, Gould L, Serena TE, Carter MJ, Keller J, Li WW. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. *Int Wound J.* 2015;12(6):724-732. 5. Zelen CM, Serena TE, Gould L, et al. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. *Int Wound J.* 2016;13(2):272-282. 6. Bianchi C, Cazzell S, Vayser D, et al. A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EPIFIX®) allograft for the treatment of venous leg ulcers. *Int Wound J.* 2018;15(1):114-122. 7. Bianchi C, Tettelbach W, Istwan N, et al. Variations in study outcomes relative to intention-to-treat and per-protocol data analysis techniques in the evaluation of efficacy for treatment of venous leg ulcers with dehydrated human amnion/chorion membrane allograft. *Int Wound J.* 2019;16(3):761-767.

866.477.4219 • customerservice@mimedx.com